Significant Board Changes Announced by Zimmer Biomet Holdings in 2025

Zimmer Biomet Announces Significant Board Changes

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a prominent player in the global medical technology landscape, is preparing for a notable transition within its Board of Directors. This decision, announced on February 25, 2025, aligns with the company's commitment to maintaining strong corporate governance as it continues to innovate in the medical tech sector.

Leadership Transitions

The Board changes will be highlighted by the retirement of Christopher Begley, the current Non-Executive Chairman of the Board, at the annual meeting of stockholders scheduled for May 29, 2025. Begley's departure is in compliance with the company's established governance guidelines which mandate a retirement age for directors.

Ivan Tornos, who has served as President and CEO, is set to take over as Chairman of the Board. His promotion to this pivotal position reflects his impactful leadership and strategic vision. Under his guidance, Zimmer Biomet has strengthened its position as a leader in the medical technology field, focusing on enhancing patient outcomes and shareholder value.

Meanwhile, Michael Farrell will assume the role of Lead Independent Director following the retirement of Mr. Begley. Farrell brings a wealth of experience, having been on the Zimmer Biomet Board since 2014 and currently chairing the Compensation and Management Development Committee.

Reflecting on Contributions

In discussing Begley’s imminent retirement, Tornos expressed deep gratitude for Begley's contributions since he joined the Board in 2012. Tornos highlighted the enormous impact Begley has had on the company's evolution, stating, "Chris has been a tremendous advisor and his vision, thoughtful counsel, and dedication have positioned Zimmer Biomet as a MedTech leader."

During his tenure, Begley served various important roles within the Board, including chairing the Quality, Regulatory, and Technology Committee and being an integral member of the Corporate Governance and Compensation Committees. His vast experience in the industry, including prior leadership roles at Hospira, Inc. and Hanger, Inc., contributed significantly to the successful navigation of challenges faced by the company.

Looking Forward

Tornos, now stepping into the role of Chairman, is eager to continue advancing Zimmer Biomet's mission. He stated, "I look forward to driving stronger value for our patients, shareholders, physicians, and customers in my expanded role as Chairman of the Board."

Farrell’s new role as Lead Independent Director is also seen as a strong asset to the Board's dynamic. Tornos emphasized, "We are honored to have Mick serve as our Lead Independent Director. He brings strong integrity, a collaborative approach, and a valuable strategic perspective to our Board."

About Zimmer Biomet

Zimmer Biomet is recognized not only for its long-standing history in medical technology but also for its comprehensive portfolio aimed at enhancing mobility and improving health for patients globally. The company utilizes innovative products, data analytics, and artificial intelligence to enhance the patient experience across its diverse operations in over 25 countries.

For additional information regarding Zimmer Biomet's products and services, visit zimmerbiomet.com or follow them on LinkedIn and X/Twitter.

In summary, the upcoming changes in the Board of Directors mark a significant step for Zimmer Biomet as it prepares to transition into the next chapter of its strategic innovation and leadership.